MA27539A1 - Nouvelle combinaison synergique contenant du roflumilast et du formoterol - Google Patents

Nouvelle combinaison synergique contenant du roflumilast et du formoterol

Info

Publication number
MA27539A1
MA27539A1 MA28343A MA28343A MA27539A1 MA 27539 A1 MA27539 A1 MA 27539A1 MA 28343 A MA28343 A MA 28343A MA 28343 A MA28343 A MA 28343A MA 27539 A1 MA27539 A1 MA 27539A1
Authority
MA
Morocco
Prior art keywords
formoterol
synergistic combination
combination containing
new synergistic
containing roflumilast
Prior art date
Application number
MA28343A
Other languages
English (en)
French (fr)
Inventor
Rolf Beume
Daniela Bundschuh
Norbert Kolassa
Degenhard Marx
Christian Weimar
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of MA27539A1 publication Critical patent/MA27539A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MA28343A 2002-11-27 2005-06-16 Nouvelle combinaison synergique contenant du roflumilast et du formoterol MA27539A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02026505 2002-11-27

Publications (1)

Publication Number Publication Date
MA27539A1 true MA27539A1 (fr) 2005-09-01

Family

ID=32338002

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28343A MA27539A1 (fr) 2002-11-27 2005-06-16 Nouvelle combinaison synergique contenant du roflumilast et du formoterol

Country Status (31)

Country Link
US (1) US20060142308A1 (OSRAM)
EP (1) EP1567139B1 (OSRAM)
JP (1) JP2006508994A (OSRAM)
KR (1) KR101071798B1 (OSRAM)
CN (1) CN100346777C (OSRAM)
AT (1) ATE399543T1 (OSRAM)
AU (1) AU2003292120B2 (OSRAM)
BR (1) BR0316451A (OSRAM)
CA (1) CA2506962C (OSRAM)
CO (1) CO5690570A2 (OSRAM)
CY (1) CY1110369T1 (OSRAM)
DE (1) DE60321953D1 (OSRAM)
DK (1) DK1567139T3 (OSRAM)
EA (1) EA009935B1 (OSRAM)
ES (1) ES2309357T3 (OSRAM)
HR (1) HRP20050579B1 (OSRAM)
IL (1) IL168308A (OSRAM)
IS (1) IS2575B (OSRAM)
MA (1) MA27539A1 (OSRAM)
ME (1) ME00489B (OSRAM)
MX (1) MXPA05005437A (OSRAM)
NO (1) NO334247B1 (OSRAM)
NZ (1) NZ540659A (OSRAM)
PL (1) PL216752B1 (OSRAM)
PT (1) PT1567139E (OSRAM)
RS (1) RS51081B (OSRAM)
SI (1) SI1567139T1 (OSRAM)
TN (1) TNSN05131A1 (OSRAM)
UA (1) UA83018C2 (OSRAM)
WO (1) WO2004047829A1 (OSRAM)
ZA (1) ZA200503308B (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
MXPA04008070A (es) 2003-03-10 2004-11-26 Altana Pharma Ag Novedoso proceso para la preparacion de roflumilasto.
US8663694B2 (en) * 2005-03-16 2014-03-04 Takeda Gmbh Taste masked dosage form containing roflumilast
DE102005030733A1 (de) * 2005-07-01 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
UA106422C2 (uk) * 2006-07-05 2014-08-26 Такеда Гмбх КОМБІНОВАНЕ ЗАСТОСУВАННЯ ІНГІБІТОРА PDE4 ТА ІНГІБІТОРА HMG-CоA-РЕДУКТАЗИ ДЛЯ ПРОФІЛАКТИКИ АБО ЗЦІЛЮВАЛЬНОГО ЛІКУВАННЯ ЗАПАЛЬНОГО ЗАХВОРЮВАННЯ ЛЕГЕНІВ
WO2013077830A1 (en) * 2011-11-25 2013-05-30 Mahmut Bilgic Synergistilly active combinations of roflumilast and carmoterol
US20130172303A1 (en) * 2012-01-03 2013-07-04 Forest Laboratories Holdings Ltd. Roflumilast compositions for the treatment of copd
CN110403922A (zh) * 2013-01-28 2019-11-05 理森制药股份公司 通过吸入罗氟司特n-氧化物治疗自身免疫、呼吸和/或炎性病症的方法
CN104800214A (zh) * 2014-01-27 2015-07-29 成都英诺新科技有限公司 一种罗氟司特吸入气雾剂复方及制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
HU220041B (hu) * 1993-07-02 2001-10-28 Byk Gulden Lomberg Chemische Fabrik Gmbh. Fluor-alkoxi-helyettesített benzamidszármazékok, eljárás előállításukra és ezeket a vegyületeket tartalmazó gyógyászati készítmények
IL130658A (en) * 1997-02-17 2004-07-25 Altana Pharma Ag Preparations for the treatment of ARDS or IRDS containing 3 - (cyclopropylmethoxy) - N - (3, 5 - dichloro - 4 - pyridinyl) - 4 - (difluoromethoxy) benzamide and solvent for the lungs
US6624181B1 (en) * 1997-02-28 2003-09-23 Altana Pharma Ag Synergistic combination
EP0975347B1 (de) * 1997-02-28 2008-02-20 Nycomed GmbH Synergistische kombination von pde-hemmern und adenylatcyclase-agonisten bzw. guanylcyclyse-agonisten
EP1107747A4 (en) * 1998-08-26 2003-04-23 Smithkline Beecham Corp COMPOSITIONS FOR THE TREATMENT OF PULMONARY DISEASES
US6303145B2 (en) * 1999-05-10 2001-10-16 Sepracor Inc. (S,R) formoterol methods and compositions
HRP20020158B1 (en) * 1999-08-21 2007-08-31 Altana Pharma Ag Action of synergistic combination
GB0103630D0 (en) * 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
EP1370521B1 (en) * 2001-03-22 2007-12-19 Glaxo Group Limited Formanilide derivatives as beta2-adrenoreceptor agonists
PL366937A1 (en) * 2001-04-30 2005-02-07 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha

Also Published As

Publication number Publication date
HRP20050579A2 (hr) 2006-04-30
PL216752B1 (pl) 2014-05-30
CN100346777C (zh) 2007-11-07
MXPA05005437A (es) 2005-08-03
CA2506962C (en) 2012-01-03
SI1567139T1 (sl) 2008-12-31
ATE399543T1 (de) 2008-07-15
DE60321953D1 (de) 2008-08-14
NO334247B1 (no) 2014-01-20
CN1713903A (zh) 2005-12-28
RS20050382A (sr) 2007-08-03
KR101071798B1 (ko) 2011-10-11
PT1567139E (pt) 2008-10-01
ME00489B (me) 2011-10-10
HK1081861A1 (en) 2006-05-26
BR0316451A (pt) 2005-10-11
AU2003292120B2 (en) 2010-01-21
CY1110369T1 (el) 2015-04-29
IL168308A (en) 2010-12-30
TNSN05131A1 (en) 2007-05-14
EP1567139B1 (en) 2008-07-02
RS51081B (sr) 2010-10-31
IS7898A (is) 2005-06-20
UA83018C2 (uk) 2008-06-10
NO20052999L (no) 2005-06-17
EP1567139A1 (en) 2005-08-31
KR20050085104A (ko) 2005-08-29
IS2575B (is) 2010-02-15
WO2004047829A1 (en) 2004-06-10
AU2003292120A1 (en) 2004-06-18
CO5690570A2 (es) 2006-10-31
EA009935B1 (ru) 2008-04-28
ZA200503308B (en) 2006-11-29
CA2506962A1 (en) 2004-06-10
PL377732A1 (pl) 2006-02-06
NZ540659A (en) 2007-05-31
WO2004047829A8 (en) 2005-06-30
JP2006508994A (ja) 2006-03-16
EA200500774A1 (ru) 2005-12-29
DK1567139T3 (da) 2008-11-03
US20060142308A1 (en) 2006-06-29
ES2309357T3 (es) 2008-12-16
HRP20050579B1 (hr) 2014-01-31

Similar Documents

Publication Publication Date Title
TNSN07063A1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
ATE320800T1 (de) Synergistische kombination von roflumilast und salmeterol
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
ATE318601T1 (de) Zusammensetzungen zur behandlung des schnupfens, welche ipratropium und xylometazolin enthalten
GB0012362D0 (en) Chemical compounds
DK1051155T3 (da) Nasale opløsninger
MA29227B1 (fr) 4-phenyltetrahydroisoquinoline substituees, leur procedes de fabrication, leur utilisation en tant que medicament et medicament les contenant
MXPA05009986A (es) Tratamiento de la enfermedad de alzheimer.
MA27539A1 (fr) Nouvelle combinaison synergique contenant du roflumilast et du formoterol
SE0102055D0 (sv) New Compounds
MA27751A1 (fr) 4-phényltétrahydroisoquinolines substituées, procédé de production de ces composés, utilisation de ces composés en tant que médicaments et médicament contenant de tels composés
UA42719C2 (uk) Сполуки, композиції та способи, які інгібують протеази, для лікування та профілактики імуномедіаторних запальних хвороб
DK1656131T3 (da) Anvendelse af betain til behandling claudicatio intermittens
BR9915123A (pt) Composição de uma substância farmaceuticamente ativa e dispensador
MXPA04002560A (es) Combinacion de un nsaid y un inhibidor pde-4.
GEP20053512B (en) S-Methyl-Dihydro-Ziprasidone for Treatment of Psychiatric and Ocular Disorders.
EA200500865A1 (ru) Синергетическая комбинация, включающая рофлумиласт и r,r-формотерол
MA28266A1 (fr) Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles bipolaires
MD2875F1 (en) Remedy for nasal congestion treatment
ATE320817T1 (de) Antiglaukomatoses mittel und dessen verwendung
DE60126504D1 (de) Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa
TNSN01081A1 (fr) Compositions de s-methyl-dihydro-ziprasidone
MA27291A1 (fr) Acides phenoxyacetiques substitues